AUTHOR=Kilic Hatice , Arguder Emine , Karalezli Aysegul , Unsal Ebru , Guner Rahmet , Kayaslan Bircan , Hasanoglu İmran , Ates İhsan , Civak Musa , Akpınar Esmehan , Parlak Ebru , Sadi Filiz , Kocaman Yasin , Günay Sibel , Metan Esra , Er Mukremin , Dalkıran Aynil , Hezer Habibe , Ergüden Hülya , Hancıoğlu Zeynep , Kalem Ayşe , Eser Fatma , Aypak Adalet , Akıncı Esragül , Karahmetoğlu Selma , Gemcioglu Emin , Kalkan Emra , İnan Osman , Yilmaz Abdulrezzak , Güler Bagdagul , Çopuroğlu Esra , Turan İşil , Gökmen Derya , Hayme Serhat , Surel Aziz Ahmet TITLE=Effect of chronic lung diseases on mortality of prevariant COVID-19 pneumonia patients JOURNAL=Frontiers in Medicine VOLUME=9 YEAR=2022 URL=https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2022.957598 DOI=10.3389/fmed.2022.957598 ISSN=2296-858X ABSTRACT=Background

The aim of the study is to assess the effect of chronic lung disease on mortality in patients hospitalized with the diagnosis of prevariant COVID-19 Pneumonia compared to patients without chronic lung disease.

Research design and methods

A cohort of 1,549 patients admitted to the pandemic clinic with a COVID-19 Pneumonia diagnosis was analyzed. Group 1 and Group 2 were compared in terms of the treatment they received, admission to intensive care, mortality and follow-up parameters.

Results

The patient group with COVID-19 and lung disease consisted of 231 participants (14.91%) (Group 1). The patient group with COVID-19 but without lung disease had 1,318 participants (85.19%). Group 1 cases were found to receive more oxygen therapy and mechanical ventilation than Group 2 cases (p ≤ 0.001), Following univariate and multiple logistic regression analyses, it was determined that patients with chronic lung disease had a 25.76% higher mortality risk [OR: 25.763, 95% CI (Lower-Upper) (2.445–271.465), p = 0.007].

Conclusion

It was found that chronic lung disease contributed significantly to mortality in this study. Among chronic lung diseases, Chronic Obstructive Pulmonary Disease (COPD), lung cancer and interstitial lung diseases (ILDs) were shown to be more effective than other chronic lung diseases in patients with prevariant COVİD-19 population.